Skip to content

Total debt at other companies

Allogene Therapeutics logo
Allogene TherapeuticsALLO
$81.05M-8.9%
Regenxbio logo
RegenxbioRGNX
$71.07M-11.0%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$2.86M-65.0%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Johnson & Johnson logo
Johnson & JohnsonJNJ
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $1.04M.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s total debt?
Immix Biopharma, Inc. (IMMX) reported total debt of $1.04M in Q1 2026.
How has Immix Biopharma, Inc.'s total debt changed year-over-year?
Immix Biopharma, Inc.'s total debt decreased by 2.0% year-over-year, from $1.06M to $1.04M.
What is the long-term trend for Immix Biopharma, Inc.'s total debt?
Over 2 years (2020 to 2025), Immix Biopharma, Inc.'s total debt has grown at a -48.5% compound annual growth rate (CAGR), from $4.05M to $1.07M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.